Allarity Therapeutics, Inc.
stenoparib
advanced ovarian cancer
Resolved
7days ago
Catalyst readout · Jun 30, 2026
What's at stake
A key catalyst for stenoparib (advanced ovarian cancer) is expected Jun 30, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancer”